Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

Por Nicola Ferrante, Daniela Ritrovato, Rossella Bitonti, Gianluca Furneri
Publicado em 2022-04-01

[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]

Por Gianluca Furneri, Laura Santoni, Chiara Marchesi, Sergio Iannazzo, Paolo Angelo Cortesi, Achille Patrizio Caputi, Lorenzo Giovanni Mantovani
Publicado em 2016-06-01